Mumbai, Aug. 13 -- Profit before tax (PBT) increased 34.36% YoY to Rs 47.55 crore in Q1 FY27.

EBITDA stood at Rs 51.70 crore, registering the growth of 32.29% compared with Rs 31.08 crore posted in Q1 FY26.

The company is targeting revenue of Rs 1,000 crore over the next three years, as part of its broader strategy to achieve an annual growth rate of 15-18%. The company expects its growth to be supported by strong performance across key therapeutic segments including cardiac, diabetic, dermatology and ENT.

The company remains focused on expanding its presence across regulated and semi-regulated markets. It currently exports to more than 60 countries across East and West Africa, Central and North America, Latin America and Southeast Asi...